1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Vitamin E & Pioglitazone
        1.2.3 Obeticholic Acid (OCA)
        1.2.4 Elafibranor
        1.2.5 Selonsertib & Cenicriviroc
    1.3 Market by Application
        1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital Pharmacy
        1.3.3 Online Provider
        1.3.4 Retail Pharmacy
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2017-2028)
    2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Region
        2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Region (2017-2022)
        2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2023-2028)
    2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics
        2.3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends
        2.3.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
        2.3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
        2.3.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue
        3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2017-2022)
        3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2017-2022)
    3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
    3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
        3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2021
    3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players Head office and Area Served
    3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
    3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type
    4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2017-2022)
    4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2023-2028)
5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application
    5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2017-2022)
    5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2017-2028)
    6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
        6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022)
        6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028)
        6.2.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028)
    6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
        6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022)
        6.3.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028)
        6.3.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028)
    6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
        6.4.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2017-2022)
        6.4.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2017-2028)
    7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
        7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022)
        7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028)
        7.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028)
    7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
        7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022)
        7.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028)
        7.3.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028)
    7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
        7.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2017-2022)
        7.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2017-2028)
    8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
        8.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028)
    8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
        8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028)
    8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region
        8.4.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2017-2028)
    9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
        9.2.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022)
        9.2.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028)
        9.2.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028)
    9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
        9.3.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022)
        9.3.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028)
        9.3.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028)
    9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
        9.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2017-2022)
        9.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2017-2028)
    10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
        10.2.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2017-2028)
    10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
        10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2017-2028)
    10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
        10.4.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 AstraZeneca
        11.1.1 AstraZeneca Company Details
        11.1.2 AstraZeneca Business Overview
        11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.1.5 AstraZeneca Recent Developments
    11.2 Conatus Pharmaceuticals
        11.2.1 Conatus Pharmaceuticals Company Details
        11.2.2 Conatus Pharmaceuticals Business Overview
        11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.2.5 Conatus Pharmaceuticals Recent Developments
    11.3 Enzo Biochem
        11.3.1 Enzo Biochem Company Details
        11.3.2 Enzo Biochem Business Overview
        11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.3.5 Enzo Biochem Recent Developments
    11.4 Galmed Pharmaceuticals
        11.4.1 Galmed Pharmaceuticals Company Details
        11.4.2 Galmed Pharmaceuticals Business Overview
        11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.4.5 Galmed Pharmaceuticals Recent Developments
    11.5 Genfit
        11.5.1 Genfit Company Details
        11.5.2 Genfit Business Overview
        11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.5.5 Genfit Recent Developments
    11.6 Gilead
        11.6.1 Gilead Company Details
        11.6.2 Gilead Business Overview
        11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.6.5 Gilead Recent Developments
    11.7 Horizon Pharma
        11.7.1 Horizon Pharma Company Details
        11.7.2 Horizon Pharma Business Overview
        11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.7.5 Horizon Pharma Recent Developments
    11.8 Immuron
        11.8.1 Immuron Company Details
        11.8.2 Immuron Business Overview
        11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.8.5 Immuron Recent Developments
    11.9 Intercept Pharmaceuticals
        11.9.1 Intercept Pharmaceuticals Company Details
        11.9.2 Intercept Pharmaceuticals Business Overview
        11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.9.5 Intercept Pharmaceuticals Recent Developments
    11.10 Novo Nordisk
        11.10.1 Novo Nordisk Company Details
        11.10.2 Novo Nordisk Business Overview
        11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
        11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
        11.10.5 Novo Nordisk Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Vitamin E & Pioglitazone
    Table 3. Key Players of Obeticholic Acid (OCA)
    Table 4. Key Players of Elafibranor
    Table 5. Key Players of Selonsertib & Cenicriviroc
    Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2017-2022)
    Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2023-2028)
    Table 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
    Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
    Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
    Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
    Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Players (2017-2022)
    Table 18. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2021)
    Table 19. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
    Table 23. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2017-2022)
    Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2023-2028)
    Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Application (2017-2022)
    Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Application (2023-2028)
    Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 37. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 43. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 44. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 45. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 46. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 49. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 50. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2023-2028) & (US$ Million)
    Table 51. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 52. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 53. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 54. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 55. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 56. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 57. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2023-2028) & (US$ Million)
    Table 61. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 62. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 63. AstraZeneca Company Details
    Table 64. AstraZeneca Business Overview
    Table 65. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 66. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 67. AstraZeneca Recent Developments
    Table 68. Conatus Pharmaceuticals Company Details
    Table 69. Conatus Pharmaceuticals Business Overview
    Table 70. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 71. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 72. Conatus Pharmaceuticals Recent Developments
    Table 73. Enzo Biochem Company Details
    Table 74. Enzo Biochem Business Overview
    Table 75. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 76. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 77. Enzo Biochem Recent Developments
    Table 78. Galmed Pharmaceuticals Company Details
    Table 79. Galmed Pharmaceuticals Business Overview
    Table 80. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 81. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 82. Galmed Pharmaceuticals Recent Developments
    Table 83. Genfit Company Details
    Table 84. Genfit Business Overview
    Table 85. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 86. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 87. Genfit Recent Developments
    Table 88. Gilead Company Details
    Table 89. Gilead Business Overview
    Table 90. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 91. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 92. Gilead Recent Developments
    Table 93. Horizon Pharma Company Details
    Table 94. Horizon Pharma Business Overview
    Table 95. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 96. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 97. Horizon Pharma Recent Developments
    Table 98. Immuron Company Details
    Table 99. Immuron Business Overview
    Table 100. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 101. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 102. Immuron Recent Developments
    Table 103. Intercept Pharmaceuticals Company Details
    Table 104. Intercept Pharmaceuticals Business Overview
    Table 105. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 106. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 107. Intercept Pharmaceuticals Recent Developments
    Table 108. Novo Nordisk Company Details
    Table 109. Novo Nordisk Business Overview
    Table 110. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product
    Table 111. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million)
    Table 112. Novo Nordisk Recent Developments
    Table 113. Research Programs/Design for This Report
    Table 114. Key Data Information from Secondary Sources
    Table 115. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2021 VS 2028
    Figure 2. Vitamin E & Pioglitazone Features
    Figure 3. Obeticholic Acid (OCA) Features
    Figure 4. Elafibranor Features
    Figure 5. Selonsertib & Cenicriviroc Features
    Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2021 VS 2028
    Figure 7. Hospital Pharmacy Case Studies
    Figure 8. Online Provider Case Studies
    Figure 9. Retail Pharmacy Case Studies
    Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
    Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region: 2021 VS 2028
    Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2021
    Figure 15. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2021)
    Figure 16. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2021
    Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Type (2017-2028)
    Figure 19. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Application (2017-2028)
    Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Country (2017-2028)
    Figure 21. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Type (2017-2028)
    Figure 25. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Application (2017-2028)
    Figure 26. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Country (2017-2028)
    Figure 27. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 34. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Type (2017-2028)
    Figure 35. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Application (2017-2028)
    Figure 36. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Region (2017-2028)
    Figure 37. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 43. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 44. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Type (2017-2028)
    Figure 45. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Application (2017-2028)
    Figure 46. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Country (2017-2028)
    Figure 47. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY (2017-2028) & (US$ Million)
    Figure 50. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Type (2017-2028)
    Figure 51. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Market Share by Application (2017-2028)
    Figure 52. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Country (2017-2028)
    Figure 53. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 57. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 58. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 59. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 60. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 61. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 62. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 63. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 64. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 65. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed